Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa
- PMID: 11207513
- DOI: 10.1046/j.1365-2036.2001.00888.x
Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa
Abstract
Background: Intragastric growth of non-Helicobacter pylori bacteria commonly occurs during acid-suppressive therapy. The long-term clinical consequences are still unclear.
Aim: To investigate the luminal and mucosal bacterial growth during gastric acid inhibition, in relation to the type and duration of acid-inhibitory treatment, as well as to concomitant H. pylori infection.
Methods: A total of 145 patients on continuous acid inhibition with either proton pump inhibitors (n=109) or histamine2-receptor antagonists (H(2)RAs, n=36) for gastro-oesophageal reflux disease, and 75 dyspeptic patients without acid inhibition (control group) were included. At endoscopy, fasting gastric juice was obtained for pH measurement and bacteriological culture. Gastric biopsy specimens were examined for detection of H. pylori (immunohistochemistry) and of non-H. pylori bacteria (modified Giemsa stain-positive and immunohistochemistry-negative at the same location).
Results: Non-H. pylori flora was detected in the gastric juice of 92 (41.8%) patients and in the gastric mucosa of 109 (49.6%) patients. In gastric juice, prevalence rate for non-H. pylori bacteria was higher in patients taking proton pump inhibitors than controls and those taking H(2)RAs (58.7% vs. 22.6% and vs. 30.6%, P < 0.0001 and P < 0.003, respectively), but did not differ statistically between H(2)RAs and controls. In gastric mucosa, prevalence rates for non-H. pylori bacteria were higher in patients taking proton pump inhibitors and H(2)RAs than in the controls (antrum: 46.9% and 48.6% vs. 25%, P < 0.05 for both; corpus: 52.2% and 56.8% vs. 23.7%, P < 0.001 for both), but did not differ between proton pump inhibitors and H(2)RAs. Both luminal and mucosal growth of non-H. pylori bacteria were significantly greater in H. pylori-positive than -negative patients taking proton pump inhibitors (P < 0.05 for both). Luminal growth of non-H. pylori flora increased with the intragastric pH level, whilst mucosal bacterial growth increased with the duration of acid inhibition.
Conclusions: Non-H. pylori flora not only contaminates the gastric juice but also colonizes the gastric mucosa of a large proportion of patients treated long-term with acid inhibition. The relationship between H. pylori and non-H. pylori bacteria in the pathogenesis of atrophic gastritis and gastric cancer needs further elucidation.
Similar articles
-
Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.Aliment Pharmacol Ther. 2001 Aug;15(8):1163-75. doi: 10.1046/j.1365-2036.2001.01029.x. Aliment Pharmacol Ther. 2001. PMID: 11472319
-
Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.Aliment Pharmacol Ther. 1999 Feb;13(2):145-53. doi: 10.1046/j.1365-2036.1999.00466.x. Aliment Pharmacol Ther. 1999. PMID: 10102943
-
Ongoing gastric acid inhibition is a confounding factor in Helicobacter pylori diagnosis.Eur J Gastroenterol Hepatol. 1997 Jan;9(1):49-53. doi: 10.1097/00042737-199701000-00013. Eur J Gastroenterol Hepatol. 1997. PMID: 9031899
-
Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent?Scand J Gastroenterol Suppl. 1998;225:32-5. doi: 10.1080/003655298750027191. Scand J Gastroenterol Suppl. 1998. PMID: 9515750 Review.
-
Potential mechanism of corpus-predominant gastritis after PPI therapy in Helicobacter pylori-positive patients with GERD.World J Gastroenterol. 2014 Sep 14;20(34):11962-5. doi: 10.3748/wjg.v20.i34.11962. World J Gastroenterol. 2014. PMID: 25232231 Free PMC article. Review.
Cited by
-
Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Ther Adv Med Oncol. 2022 Jul 15;14:17588359221111703. doi: 10.1177/17588359221111703. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35860836 Free PMC article.
-
Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study.J Cancer Epidemiol. 2021 Dec 2;2021:2670502. doi: 10.1155/2021/2670502. eCollection 2021. J Cancer Epidemiol. 2021. PMID: 34899912 Free PMC article.
-
The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events.Drugs. 2019 May;79(7):715-731. doi: 10.1007/s40265-019-01110-3. Drugs. 2019. PMID: 30972661 Review.
-
The effect of helminth infection on the microbial composition and structure of the caprine abomasal microbiome.Sci Rep. 2016 Feb 8;6:20606. doi: 10.1038/srep20606. Sci Rep. 2016. PMID: 26853110 Free PMC article.
-
A Novel Characteristic Gastric Mucus Named "Web-like Mucus" Potentially Induced by Vonoprazan.J Clin Med. 2024 Jul 11;13(14):4070. doi: 10.3390/jcm13144070. J Clin Med. 2024. PMID: 39064109 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical